Challenges and opportunities in the development of metal-based anticancer theranostic agents

Shreyas P. Vaidya, Shubhankar Gadre, Ravi Teja Kamisetti, Malay Patra*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Around 10 million fatalities were recorded worldwide in 2020 due to cancer and statistical projections estimate the number to increase by 60% in 2040. With such a substantial rise in the global cancer burden, the disease will continue to impose a huge socio-economic burden on society. Currently, the most widely used clinical treatment modality is cytotoxic chemotherapy using platinum drugs which is used to treat variety of cancers. Despite its clinical success, critical challenges like resistance, off-target side effects and cancer variability often reduce its overall therapeutic efficiency. These challenges require faster diagnosis, simultaneous therapy and a more personalized approach toward cancer management. To this end, small-molecule 'theranostic' agents have presented a viable solution combining diagnosis and therapy into a single platform. In this review, we present a summary of recent efforts in the design and optimization of metal-based small-molecule 'theranostic' anticancer agents. Importantly, we highlight the advantages of a theranostic candidate over the purely therapeutic or diagnostic agent in terms of evaluation of its biological properties.

Original languageEnglish
Article numberBSR20212160
JournalBioscience Reports
Issue number5
StatePublished - May 2022
Externally publishedYes


Dive into the research topics of 'Challenges and opportunities in the development of metal-based anticancer theranostic agents'. Together they form a unique fingerprint.

Cite this